Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-06-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
董事、监事和高级管理人员所持公司股份及其变动管理制度（2022年6月）
Governance Information Classification · 95% confidence The document is titled "董事、监事和高级管理人员所持公司股份及其变动管理制度" which translates to "Management System for Shares Held and Changes by Directors, Supervisors, and Senior Management." It details rules and procedures regarding the holding, buying, selling, and disclosure of company shares by directors, supervisors, and senior management. The content includes compliance with laws, disclosure obligations, lock-up periods, reporting requirements, and internal management of share transactions by insiders. There is no indication that this is a report of financial results, audit, or a general regulatory announcement. Instead, it is a governance document outlining internal rules and policies related to insider shareholding and transactions. This fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document is substantive and detailed, not a brief announcement or certification, so it is not RNS or RPA. Therefore, the appropriate classification is CGR with high confidence.
2022-06-28 Chinese
年报信息披露重大差错责任追究制度（2022年6月）
Governance Information Classification · 95% confidence The document is titled as a '重大差错责任追究制度' which translates to 'Major Error Responsibility Accountability System' related to the annual report information disclosure of the company. It outlines the principles, scope, and procedures for accountability in case of significant errors in the annual report disclosures. The content is about internal governance and responsibility rules rather than the annual report itself or an announcement of financial results. It does not contain financial data or results but rather governance policies related to annual report disclosures. Therefore, it fits best under Governance Information (CGR) as it details internal rules and governance practices related to annual report disclosures.
2022-06-28 Chinese
独立董事年报工作制度（2022年6月）
Governance Information Classification · 95% confidence The document is titled '独立董事年报工作制度' which translates to 'Independent Directors Annual Report Work System'. It outlines the responsibilities and procedures for independent directors in relation to the company's annual report preparation and disclosure. The content focuses on governance, oversight, and internal control mechanisms related to the annual report process, rather than the annual report itself. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange concerning annual reports, but it is a governance policy document rather than a financial report or announcement. The document length is short (1113 characters) and it does not contain financial data or audit results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-06-28 Chinese
董事会秘书工作细则（2022年6月）
Board/Management Information Classification · 95% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' or 'Board/Management Information Rules'. It details the qualifications, responsibilities, appointment, and duties of the company's board secretary. It references relevant laws and regulations, and outlines internal governance procedures related to the board secretary role. There is no financial data, no report of financial results, no audit information, no voting results, no capital changes, no earnings release, no legal proceedings, no merger or acquisition activity, and no investor presentation. The document is a governance-related internal rules document about board/management roles and responsibilities. Therefore, it fits best under the category 'Board/Management Information' (MANG). The document length is 7499 characters, which is substantive and not a mere announcement or certification. Hence, the classification is MANG with high confidence.
2022-06-28 Chinese
对外投资管理制度（2022年6月）
Governance Information Classification · 95% confidence The document is titled '健帆生物科技集团股份有限公司 对外投资管理制度' which translates to 'JH Biotech Group Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining principles, approval procedures, management, and disclosure related to the company's external investments. It references relevant laws and regulations but does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief summary but a formal internal governance document. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices. The document length is 4193 characters, which is consistent with a detailed policy document rather than a short announcement or a full annual/interim report.
2022-06-28 Chinese
董事会议事规则（2022年6月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors Meetings' of 健帆生物科技集团股份有限公司. It details the procedures, rules, and governance related to the board meetings, including meeting notices, voting, quorum, and record keeping. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not an announcement or a brief notice, but a detailed governance document.
2022-06-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.